

WE CLAIM:

1. An anti-IFNAR1 monoclonal antibody that inhibits the anti-viral activity of a first type I interferon and does not inhibit the anti-viral activity of a second type I interferon selected from
5 the group consisting of IFN- α A, IFN- α B, IFN- α 1, and IFN- β .
2. The monoclonal antibody of claim 1 wherein the second type I interferon is IFN- β .
3. The monoclonal antibody of claim 2 wherein the first type I interferon is selected from
10 the group consisting of IFN- α A, IFN- α B, and IFN- α G.
4. The monoclonal antibody of claim 3 that inhibits the anti-viral activity of IFN- α A, IFN- α B, and IFN- α G.
- 15 5. The monoclonal antibody of claim 4 that is designated 4A7, having ATCC Deposit No. HB12132.
6. The monoclonal antibody of claim 4, wherein the antibody recognizes a conformational epitope on IFNAR1.
20
7. The monoclonal antibody of claim 6, wherein the antibody does not bind to a peptide consisting of the amino acid sequence of domain 1 (amino acids 1-200) of IFNAR1 and does not bind to a peptide consisting of the amino acid sequence of domain 2 (amino acids 204-404) of IFNAR1.
25
8. The monoclonal antibody of claim 4 that binds to one or more amino acids in situ in the

sequence of amino acids 244-249 of IFNAR1, and binds to one or more amino acids in situ in the sequence of amino acids 291-298 of IFNAR1.

9. The monoclonal antibody of claim 8 that binds to amino acids 249, 291 and 296 of
5 IFNAR1 in situ.

10. The monoclonal antibody of claim 9 that is designated 2E1, having ATCC Deposit No.
HB 12133.